Taro/TARO

$42.08

0.04%
-
1D1W1MYTD1YMAX

About Taro

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets over 200 pharmaceutical products in over 25 countries. The Company's owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The Company's other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.

Ticker

TARO

Sector

Healthcare

Trading on

NYSE

Industry

Biotechnology & Drugs

CEO

Uday Baldota

Employees

1,554

Headquarters

Haifa, Israel

Taro Metrics

BasicAdvanced
$1.58B
Market cap
34.59
P/E ratio
$1.22
EPS
0.61
Beta
-
Dividend rate

What the Analysts think about Taro

Analyst Ratings

Majority rating from 1 analysts.
Hold

Price Targets

Average projection from 1 analysts.
2.19% upside
High $43.00
Low $43.00
$42.08
Current price
$43.00
Average price target

Taro Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
12.85% profit margin
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$157.1M
6.01%
Net income
$20.2M
137.65%
Profit margin
12.85%
124.26%

Taro Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 80%
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$0.18
$0.27
$0.23
$0.54
-
Expected
$0.23
$0.31
$0.18
$0.30
$0.31
Surprise
-21.74%
-12.9%
27.78%
80%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Taro stock

Buy or sell Taro stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing